ROOT OF SKIN™ Skincare Line Sets Records in Fourth Consecutive Sell Out on QVC Japan
IRVINE, Calif. – January 25, 2019 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that the Company’s revolutionary stem-cell based ROOT OF SKIN™ skincare line sold out again during its fourth appearance on the Japanese home shopping channel QVC Japan. The segment selling ROOT OF SKIN™ Revitalizing Face Renewal Serum and ROOT OF SKIN™ Revitalizing Eye Renewal Complex aired at 3am on January 24, 2019, with both products selling out within 10 minutes of the start of the segment, setting a QVC Japan record.
ROOT OF SKIN™ is AIVITA’s proprietary skincare line for skin rejuvenation, made possible through the same proprietary knowledge and expertise used to develop its cutting-edge stem cell therapies. The all-new actives complex SourceCode Technology™ contains the complete set of factors and supporting biological components present in young, healthy skin.
“We’ve been told by production staff that this is potentially the quickest ever product sellout on QVC Japan,” said Christi Douglass, AIVITA’s Marketing and Business Development Officer. “Success in this prestige market is a reflection of our superior product.”
AIVITA Biomedical uses 100% of the proceeds from ROOT OF SKIN™ sales to support the treatment of women with ovarian cancer.
About ROOT OF SKIN™
ROOT OF SKIN™ is a rejuvenating line of skincare products fueled by an unrelenting pursuit for advancements in life-changing and life-saving treatments. Harnessing breakthroughs in stem cell therapy, AIVITA Biomedical developed a technology that does more than just boost regeneration. The patented actives complex SourceCode Technology™ renews, repairs and protects, just as your skin did at its youngest and healthiest stage. Rich with every biological component healthy skin needs for development, and free of any unnecessary ingredients. All proceeds support treatment of women with ovarian cancer.
About AIVITA Biomedical
AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products.